2021
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, Kinahan C, Francescone MM, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes D, Scotto L, Sokol L, Shustov AR, O’Connor O. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood 2021, 137: 2161-2170. PMID: 33171487, DOI: 10.1182/blood.2020009004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsAzacitidineDepsipeptidesDNA MethylationFemaleHistone Deacetylase InhibitorsHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedMutationTreatment OutcomeConceptsPeripheral T-cell lymphomaOverall response rateMedian progression-free survivalProgression-free survivalT-cell lymphomaOverall survivalR Peripheral T Cell LymphomaResponse rateFollicular helper cell phenotypeMulticenter phase 2 studyHigher overall response rateFrequent grade 3Complete response rateComplete remission ratePhase 2 studyPhase 1 trialDuration of responseHelper cell phenotypeLonger median survivalHistone deacetylase inhibitorsPTCL patientsR diseaseTreatment-naïveMedian survivalRemission rate
2019
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
O’Connor O, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood 2019, 134: 1395-1405. PMID: 31471376, DOI: 10.1182/blood.2019001285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsDepsipeptidesDrug Administration ScheduleFemaleHumansLymphoma, T-CellMaleMiddle AgedTreatment OutcomeYoung AdultConceptsPeripheral T-cell lymphomaPhase 1 studyDay 1Day 8Response rateMulticenter phase 1 studyT-cell lymphoma patientsAdvanced lymphoid malignanciesTreatment-related deathsComplete response rateCoprimary end pointsGrade 3 thrombocytopeniaGrade 4 neutropeniaGrade 4 thrombocytopeniaOverall response rateT-cell lymphomaNon-T-cell lymphomasTumor mutational profileHistone deacetylase inhibitorsPTCL patientsPleural effusionLymphoma patientsLymphoid malignanciesEpigenetic modifiersPatients
2008
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBleomycinBone Marrow PurgingCombined Modality TherapyCyclophosphamideCytarabineDisease ProgressionDisease-Free SurvivalDoxorubicinDrug Administration ScheduleEtoposideFemaleFollow-Up StudiesGenes, bcl-2Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansImmunologic FactorsImmunosuppressive AgentsKaplan-Meier EstimateLymphoma, FollicularMaleMiddle AgedMultivariate AnalysisPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionRituximabTime FactorsTransplantation, AutologousTreatment OutcomeVincristineConceptsProgression-free survivalRefractory follicular lymphomaHigh-dose therapyFollicular lymphomaFive-year progression-free survivalPeripheral blood stem cell mobilizationBlood stem cell mobilizationEnd pointHigh-dose AraC.Persistent clinical remissionPrimary end pointSecondary end pointsStem cell harvestStem cell mobilizationBcl-2 rearrangementClinical remissionComplete remissionMolecular remissionPartial responseComplete responseClinical outcomesCell mobilizationMedian numberImmunochemotherapyPatients
2006
Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease
Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E, Lazzarino M, Linfomi I. Primary nodal marginal zone B‐cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal Of Haematology 2006, 136: 301-304. PMID: 17233821, DOI: 10.1111/j.1365-2141.2006.06437.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleHepacivirusHepatitis CHumansImmunophenotypingLymphoma, B-CellMaleMiddle AgedMultivariate AnalysisPrednisonePrognosisRare DiseasesSurvival AnalysisVincristineConceptsFollicular Lymphoma International Prognostic IndexOverall survivalClinical featuresPrimary nodal marginal zone B-cell lymphomaHepatitis C virus serologyMarginal zone B-cell lymphomaNodal marginal zone B-cell lymphomaC virus serologyStage IV diseaseWorse overall survivalInternational Prognostic IndexB-cell lymphomaWorse OSPrognostic indexVirus serologyPrognostic assessmentRare diseaseMultivariate analysisLactate dehydrogenaseDiseasePatientsPrognosisLymphomaSerologyNongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination
Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M. Nongastric Marginal-Zone B-Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. The Oncologist 2006, 11: 285-291. PMID: 16549813, DOI: 10.1634/theoncologist.11-3-285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnthracyclinesAntibodies, MonoclonalAntigens, CD20Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow NeoplasmsChemotherapy, AdjuvantFemaleFollow-Up StudiesHumansItalyLymphatic MetastasisLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedMultivariate AnalysisPrognosisRadiotherapy, AdjuvantRetrospective StudiesConceptsBone marrow involvementMarrow involvementNodal involvementClinical featuresSurvival timeBone marrowMedian event-free survival timeB-cell MALT lymphomaMedian overall survival timeDisease disseminationEvent-free survival timeB-cell mucosaStage IV diseaseOverall survival timeLymphoid tissue lymphomaMarginal zone lymphomaLonger EFSNodal diseaseShorter OSOS timeTissue lymphomaWaldeyer's ringPoor outcomePrognostic significancePrognostic value
2004
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation 2004, 34: 1039-1045. PMID: 15516936, DOI: 10.1038/sj.bmt.1704717.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBlood TransfusionFemaleGraft SurvivalHematologic NeoplasmsHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionSurvival AnalysisThiotepaTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousVidarabineConceptsAllogeneic blood stem cell transplantationPeripheral stem cell transplantBlood stem cell transplantationReduced-intensity conditioning regimenStandard myeloablative regimenTransplant-related mortalityPoor performance statusStem cell transplantStem cell transplantationOverall survival probabilityMyeloablative regimenNonrelapse causesComplete remissionConditioning regimenMild nauseaPreparative regimenAdverse eventsPerformance statusMedian ageRBC transfusionCell transplantCell transplantationHaematological malignanciesSerum amylasePatientsA model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma
Arcaini L, Orlandi E, Alessandrino EP, Iacona I, Brusamolino E, Bonfichi M, Bernasconi P, Calatroni S, Tenore A, Montanari F, Troletti D, Pascutto C, Regazzi M, Lazzarino M. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Bone Marrow Transplantation 2004, 34: 175-179. PMID: 15170171, DOI: 10.1038/sj.bmt.1704551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsB-LymphocytesBone Marrow PurgingCytarabineFemaleHematopoietic Stem Cell MobilizationHumansImmunophenotypingLymphoma, FollicularLymphoma, Mantle-CellMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRituximabSalvage TherapyTransplantation, AutologousConceptsB-cell depletionHD cytarabineB cellsCell lymphomaPeripheral blood stem cell mobilizationBlood stem cell mobilizationRefractory mantle cell lymphomaHigh-dose AraCRefractory follicular lymphomaHigh-dose cytarabineCombination of rituximabGranulocyte colony-stimulating factorCollection of PBSCStem cell mobilizationMantle cell lymphomaColony-stimulating factorHD chemotherapyPeripheral CD19Concurrent administrationIndolent lymphomaPeripheral bloodPatients PCRProfound depletionCell mobilizationMedian number